Ralf Gutzmer

发表

Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM

M. Weichenthal, J. Utikal, J. Klode, 2023, EBioMedicine.

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.

J. Utikal, C. Berking, D. Schadendorf, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma

M. Weichenthal, D. Schadendorf, F. Kiecker, 2023, Cancers.

A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.

J. Utikal, C. Berking, D. Schadendorf, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG

M. Weichenthal, A. Hauschild, S. Haferkamp, 2023, Journal for ImmunoTherapy of Cancer.

Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity

K. Thoms, P. Bröckelmann, Rafaela Kramer, 2024, Frontiers in cardiovascular medicine.

Treatment of Advanced Cutaneous Squamous Cell Carcinomas with Epidermal Growth Factor Receptor Inhibitors

M. Alter, R. Gutzmer, A. Kapp, 2013, Dermatology.

Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade.

K. Kähler, C. M. Thielmann, Emmanouil Gratsias, 2024, European journal of cancer.

Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events

S. Haferkamp, A. Gesierich, K. Kähler, 2024, Frontiers in immunology.

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.

A. Sucker, F. Meier, A. Paschen, 2024, European journal of cancer.

Early versus late response to PD-1-based immunotherapy in metastatic melanoma.

P. Jansen, A. Sucker, B. Hellwig, 2024, European journal of cancer.

Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.

I. Pires da Silva, Jorja Braden, P. Serra-Bellver, 2024, European journal of cancer.

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.

P. Ascierto, I. Krajsová, A. Arance, 2024, European journal of cancer.

PTHrP-induced hypercalcemic psychosyndrome under combined anti-PD-L1 and anti-EGFR inhibition in penile squamous cell carcinoma – a case report

Lea-Jessica Albrecht, Anne-Christine Müseler, Ralf Gutzmer, 2024, EJC Skin Cancer.

Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.

A. Gesierich, A. Forschner, F. Meier, 2024, European journal of cancer.

The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.

K. Kähler, P. Ascierto, J. Wolchok, 2023, European journal of cancer.

Immune checkpoint inhibition and targeted therapy for melanoma: A patient‐oriented cross‐sectional comparative multicentre study

S. Haferkamp, M. Gaiser, R. Gutzmer, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Short- and long-term immunosuppressive effects of melanoma influence the prognostic value of the sentinel lymph node status.

D. Schrama, Nalini Srinivas, Cathrin Ritter, 2024, European journal of cancer.